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Background: Primary progressive multiple sclerosis (PP-MS) differs from relapsing-remitting or secondary
progressive MS (RR/SP-MS) in ways suggesting differences in the pathogenic pathways. Susceptibility to
both PP-MS and RR/SP-MS is linked to carriage of the HLA molecule DRB1*1501. Several serologically
defined HLA-DR groups (DR1, DR4, DR6, and DR9) occur less often in RR/SP-MS than in controls. Some or
all of the HLA-DR molecules encoded by alleles in these serologically defined groups have a negatively
charged glutamic acid at residue 71 or 74 of the b1 chain (b171/b174). Residues at these positions are
important in the formation of pocket 4 in the antigen binding site of the HLA-DR molecule.
Objectives: To investigate whether the presence of alleles encoding HLA-DR molecules containing glutamic
acid at b171/b174 correlates with the course of MS.
Methods: HLA-DR and HLA-DQ alleles and genotypes were analysed in 121 MS patients (50 with PP-MS)
and 109 controls by molecular typing.
Results: Alleles encoding HLA-DR molecules containing a glutamic acid at b171/b174 occurred less often
in patients with RR/SP-MS than in those with PP-MS or controls. In subjects not carrying the DRB1*1501
allele, a much higher proportion of PP-MS patients carried alleles encoding HLA-DR molecules containing
a glutamic acid at b171/b174 than did RR/SP-MS patients or controls.
Conclusions: The amino acid residues involved in determining the shape and charge of pocket 4 of the
HLA-DR b1 chain could influence the clinical course of MS by determining protection against RR/SP-MS or
susceptibility to the development of PP-MS.
M
ultiple sclerosis (MS) is a chronic inflammatory
demyelinating disease of the central nervous system
(CNS). Typically, MS has a relapsing–remitting course
with clinical attacks followed by some improvement and
attack-free intervals. However, after 10–15 years of a
relapsing–remitting disease course (RR-MS), more than
50% of patients are likely to have developed a progressive
course, characterised by a slow inexorable decline in
neurological function. This form of progressive MS is known
as secondary progressive MS (SP-MS). In 10–20% of cases of
MS, a progressive course occurs from the onset of disease.
This form of MS is known as primary progressive MS (PP-
MS). PP-MS differs from RR/SP-MS in the amount of CNS
inflammation,1 age at onset,2 the female to male ratio,3 the
initial symptoms,4 and prognosis with regard to disability.2
Factors that determine the particular disease course a patient
will follow remain obscure, although an older age at onset
correlates with a greater likelihood of PP-MS.5 Natural
history studies, however, show little difference in the
progressive phases of PP-MS and SP-MS.2 6 This and the
recent report of a patient with subclinical disease for at least
10 years before the clinical onset of PP-MS7 are consistent
with the suggestion that PP-MS may differ from RR/SP-MS
only in having a subclinical initial stage of disease.6
Both PP-MS and RR/SP-MS are associated with an
increased occurrence of other autoimmune diseases in
affected individuals and their first degree relatives, suggest-
ing that they are both autoimmune disorders.8 The pathogen-
esis of MS is thought to involve the development of
autoimmunity against components of CNS myelin. This
autoimmunity appears to be driven by major histocompat-
ibility complex (MHC) class II restricted T cells,9 10 which
cannot recognise antigen directly but require that it is
presented to them on the surface of antigen presenting cells
in association with the MHC class II molecules, which in
humans are termed human leucocyte antigen (HLA)-DR,
HLA-DQ, or HLA-DP. The HLA molecules are formed from
two polypeptide chains, a and b. Some of these chains are
extremely polymorphic, particularly the HLA-DR b1 chain
and the HLA-DQ a and b chains. The amino acid sequences of
the a and b chains of the HLA molecule determine which
antigens can be bound and presented to T cells.
Immunogenetic studies in MS have shown associations
between a limited number of ancestral haplotypes and
susceptibility to MS.11–19 In particular, the haplotype
DRB1*1501–DQA1*0102–DQB1*0602 (that is, the 1501 allele
of the gene encoding the HLA-DR b1 chain, the 0102 allele
encoding the HLA-DQ a chain, and the 0602 allele encoding
the HLA-DQ b chain) correlates with development of MS in
northern Europeans, northern European derived populations,
Ashkenazi and non-Ashkenazi Jews, Turkish, Mexican
Mestizo, and some Japanese and Sardinian patients.
However, carriage of these alleles does not correlate with
the disease course in MS, as patients with PP-MS and those
with RR/SP-MS carry this haplotype in approximately equal
proportions.16 20 21
Notwithstanding the lack of correlation between
DRB1*1501 haplotype and disease course, the finding that
specific immune T cell and antibody responses against myelin
and other CNS antigens differ between PP-MS and RR/SP-
MS22–25 suggests that there may be differences in the other
HLA alleles carried by people with different disease courses.
However, while some other HLA alleles have been found to be
Abbreviations: MS, multiple sclerosis; PP, primary progressive; RR,
relapsing-remitting; SP, secondary progressive
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expressed at increased or decreased proportions in either PP-
MS or RR/SP-MS compared with controls, no significant
differences have consistently been found between PP-MS and
RR/SP-MS. Several studies have suggested a link between
carriage of DR4 alleles and PP-MS, but others have not. This
disparity has largely reflected the relatively small sample size
of PP-MS in each study (less than 20 individuals) and the
large number of HLA alleles being compared. Recently,
however, two studies with larger PP-MS sample sizes have
been reported—one from Sweden, which tested 85 PP-MS
patients, 727 RR/SP-MS patients, and 455 controls,5 and one
from Ireland, which tested 102 PP-MS patients, 202 RR/SP-
MS patients and 398 controls.21 Interestingly, both studies
showed significantly decreased frequencies of DR1, DR4,
DR6, and DR9 serologically defined HLA groups in RR/SP-MS
patients compared with controls, but no significant differ-
ences between PP-MS patients and controls; however, this
finding was not specifically mentioned in these papers.
The serologically defined HLA nomenclature (DR1, DR2,
DR3, and so on) is often used to report HLA-DR results, as it
groups together alleles that show similar reactivity to a panel
of tissue typing sera. However, it is now known that each of
these sera recognise more than one HLA amino acid
sequence. For example, the DR4 serum recognises more than
40 different HLA molecules, each differing slightly in the
amino acid sequence of the b1 chain. These slight differences
in sequence can greatly affect the ability of a particular HLA
molecule to bind and present an antigen. Thus the finding of
decreased frequencies of DR1, DR4, DR6, and DR9 in RR/SP-
MS patients compared with controls—but no significant
differences between PP-MS patients and controls—is of
interest because DR1, DR4, DR6, and DR9, together with
DR5, are the only serological groupings that contain alleles
encoding HLA-DR molecules having a negatively charged
glutamic acid at residue 71 or 74 of the b1 chain (b171 or
b174).
These two residues—together with residues 13, 70, and 78
of the b1 chain, and residues 9 and 62 of the a chain—are
important in determining the shape and charge of pocket 4 of
the antigen-binding groove of the HLA-DR molecule26 27
(fig 1). However, not all of the alleles in DR1, DR4, or DR6
serological groups encode HLA-DR molecules containing a
glutamic acid at b171 or b174. As the HLA data in the two
large studies were reported only at the level of serological
groups, it is not possible to determine whether the presence
of a glutamic acid residue at these positions is correlated
with the course of MS. The aim of the current study,
therefore, was to test the hypothesis that the frequency of
HLA-DRB1 alleles encoding HLA-DR molecules containing
glutamic acid at b171 or b174 differ in PP-MS and RR/SP-MS.
The results show that such alleles occur significantly less
often in RR/SP-MS than in PP-MS, and support the
hypothesis that, in some cases at least, HLA can influence
the clinical course of MS.
METHODS
Subjects
The 230 individuals used in this study included 50 patients
with PP-MS, 71 with RR-MS or SP-MS, and 109 unrelated
individuals of white ethnicity as controls. More than 95% of
all individuals were of northern European descent, with the
remainder being of southern European descent. The MS
patients were from Queensland and northern New South
Wales in Australia and were seen at the MS clinic, Royal
Brisbane and Women’s Hospital. All MS patients met the
criteria of Poser et al30 for definite MS. All RR/SP-MS patients
also met the criteria of McDonald et al31 for MS. Five PP-MS
patients did not meet the latter criteria, because magnetic
resonance imaging scans were not available for inspection;
however, as all these patients had had typical symptoms and
signs of PP-MS (with no superimposed relapses) for more
than 10 years they were included in the study.
DNA samples
Peripheral blood samples (5–10 ml) were collected by
venepuncture into heparinised tubes, after informed written
consent had been obtained from each subject. Red cells were
lysed and the cell pellet incubated at 37 C˚ overnight in the
presence of 0.5 mg/ml proteinase K. High molecular weight
DNA was then salted out, using the method of Miller et al.32
HLA typing
HLA-DRB1, -DQA1, and -DQB1 typing was carried out for
each DNA sample using DynalH sequence specific primer sets
according to the manufacturer’s instructions. Results of the
typing are given as specific alleles, and are also grouped
according to serologically defined groups listed by the WHO
nomenclature committee for factors of the HLA system.33
Statistical analysis
The frequencies of HLA alleles and genotypes in patients and
controls were compared using x2 analysis by 262 contingency
tables. Yates’s correction was applied when the number of
positive samples in any test was less than 5. Fisher’s exact
test was used when the total number of samples was less
than 50. Odds ratios (OR) and 95% confidence intervals (CI)
of the odds ratio for phenotype or genotype frequencies
were also calculated. Probability (p) values were corrected
for multiple comparisons using Bonferroni’s method,
according to the formula pcorrected (pc)=12(12p)
n, where p
is the uncorrected p value and n is the number of
comparisons.
Figure 1 Schematic of the putative antigen binding cleft of the HLA-
DRB1*0404 molecule, based on the known crystal structure of
DRB1*0401.28 One a helix and half of the b pleated sheet are formed
from the DR b1 chain, and the other from the DR a chain. Residues of the
peptide antigen that binds in the cleft are usually anchored in pocket 1,
pocket 4, and pocket 6 or 7. The residues in pocket 4 that differ from one
HLA-DR allele to another are shown in different colours: residues 9
(yellow) and 62 (pink) of the DR a chain and residues 13 (white), 70
(orange), 71 (green), 74 (blue), and 78 (red) of the DR b1 chain. HLA-
DRB1*0404 contains an alanine at b174, whereas HLA-DRB1*0407
contains a glutamic acid at this position, as shown in the inset. The figure
was prepared using the Swiss PDB viewer.29
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RESULTS
HLA-DRB1 phenotype frequencies
The phenotype frequencies of HLA-DRB1 alleles were
determined for 50 PP-MS, 71 RR/SP-MS, and 109 non-MS
controls. In all, there were 39 different HLA-DRB1 alleles in
the MS patients or controls in this study. In order to
determine if these populations were similar to the two
previous large HLA-DR studies, where results were given as
serologically defined groups,5 21 the data were analysed and
compared with results from those two studies (table 1). In
general, the frequencies of serologically defined HLA groups
found in our study were within 1–3% of those found
previously. The frequencies that we found for DR6 carriage
by all individuals differ more; however, they lie within the
range of frequencies found in the two large studies (25.9%,
22.7%, and 34.9% for PP-MS, RR/SP-MS, and controls,
respectively, in the study from Sweden5; and 14.7%, 9.4%,
and 18.3% in the study from Northern Ireland21), and may
reflect the mixed northern European ancestry of the white
Australian population. In addition, the proportion of RR/SP-
MS patients carrying DR2 in the current study was larger
than in either of the other two studies, although the
proportion carrying the DR15 subtype (66%) again lay
between the percentages reported from Sweden (61%) and
Northern Ireland (69%). The frequency of carriage of DR2 did
not differ in non-MS controls or PP-MS in our study and the
other two studies.
There were no significant differences between carriage of
different serologically defined HLA groups in PP-MS v RR/SP-
MS after correction for multiple comparisons. However, as
mentioned in the introduction, an interesting observation
was that the difference was much more significant (after p
values had been corrected for 19 comparisons) between the
total number of RR/SP-MS patients (pooled from the present
study and the two previous studies) and total number of
controls than between the total number of PP-MS patients
and the total number of controls for carriage of DR1
(pc=1.6610
23 v pc=0.999), DR4 (pc=5.0610
25 v
pc=0.958), DR6 (pc=4.2610
23 v pc=0.767), and DR9
(pc=6.7610
23 v pc=0.999). This is not just because of the
larger numbers of RR/SP-MS patients, and is interesting
because a common feature of these serologically defined
groups is that they all include alleles that encode HLA-DR
molecules containing a glutamic acid at b171 or b174.
None of the other serologically defined HLA-DR groups
except DR5 and DR53 (DRB4—that is, a b4 chain instead of
b1 in the HLA molecule, which is present in most DR4, DR7,
and DR9 containing haplotypes) includes alleles that encode
HLA molecules with glutamic acid residues at residues 71 or
74 of the b1 chain. We therefore looked at carriage of alleles
that did or did not encode HLA-DR molecules containing a
glutamic acid at residues 71 or 74 of the b chain by patients or
controls in our study (table 2). Whereas 40% of PP-MS
patients and 34.9% of controls carried alleles encoding HLA-
DRB1 molecules that have a glutamic acid at these positions,
only 12.7% of RR/SP-MS patients carried such alleles. Most of
this effect is caused by carriage of the DR6 alleles DRB1*1302
and *1401, which differed significantly (p=0.01) between
PP-MS and RR/SP-MS. The results suggest either that
carriage of alleles encoding HLA-DR molecules containing a
glutamic acid at b171 or b174 is protective against RR/SP-MS,
but not against PP-MS, or alternatively that such alleles
encode HLA-DRB1 molecules that are able to present
antigens that are important in the development of PP-MS,
but not RR/SP-MS. There were no significant differences
between MS patients or controls for carriage of DR53
(table 2).
Within the DR1, DR4, DR5, DR6, and DR9 groups, there
were no significant differences among PP-MS patients, RR/
SP-MS patients, or controls for carriage of alleles encoding
HLA molecules that do not contain a glutamic acid at b171 or
b174. Indeed, all of the other alleles within these groups that
were carried by the individuals studied (both MS and
controls) encode proteins that have a positively charged
arginine or lysine at residue 71 and an alanine at residue 74.
Most other studies reported using molecular typing for
HLA either do not show data for all alleles, or use a mixture
of PP-MS and RR/SP-MS patients. However, Zipp et al34
reported full HLA-DR typing for a group of 66 patients with
RR/SP-MS and 210 controls. In that dataset, there was also a
significant decrease in the proportion of RR/SP-MS patients
carrying alleles that encode HLA-DR molecules containing a
glutamic acid at b171 or b174 (16 of 66) compared with
controls (93 of 210) (OR=0.4 (0.21 to 0.75); pc=0.039),
confirming our observations.
HLA-DRB1 genotype analysis
Whereas a small proportion of MS patients are homozygous
for their HLA antigens, most express two different alleles at
each locus. There is some restriction in the number of
different HLA-DRB1 genotypes carried by MS patients
compared with controls. This is influenced by the increased
frequency of the DRB1*1501 allele in MS; in our study, both
RR/SP-MS and PP-MS HLA-DR genotypes contained this
allele significantly more often (71.4% and 62.0%, respec-
tively) than control genotypes (23.9%; OR for PP-MS v
control=5.2 (2.5 to 10.7); pc=1.4610
24, and OR for RR/SP-
MS v controls=8.0 (3.9 to 16.5); pc=1.5610
27; p values are
corrected for 42 comparisons). Of the DRB1 genotypes found
in PP-MS, 19 did not occur in RR/SP-MS patients. Notably,
Table 1 Phenotype frequencies for HLA-DR in primary progressive multiple sclerosis, relapsing-remitting/secondary
progressive multiple sclerosis, and controls
Serological
group
PP-MS RR/SP-MS Controls
Refs 5 and 21
(n = 187)
Current
(n = 50)
Total
(n = 237)
Refs 5 and 21
(n = 929)
Current
(n = 71)
Total
(n = 1000)
Refs 5 and 21
(n = 853)
Current
(n = 109)
Total
(n = 962)
01 38 (20.3%) 10 (20%) 48 (20.3%) 137 (14.7%) 9 (12.7%) 146 (14.6%) 181 (21.2%) 25 (22.9%) 206 (21.4%)
02 116 (62.0%) 31 (62%) 150 (63.3%) 591 (63.6%) 50 (70.4%) 641 (64.1%) 277 (32.5%) 34 (31.2%) 311 (32.3%)
03 49 (26.2%) 14 (28%) 63 (26.6%) 218 (23.5%) 21 (29.6%) 239 (23.9%) 221 (25.9%) 29 (26.6%) 250 (26.0%)
04 59 (31.6%) 14 (28%) 73 (30.8%) 244 (26.3%) 18 (25.4%) 262 (26.2%) 305 (35.7%) 41 (37.6%) 346 (36.0%)
05 11 (5.9%) 4 (8%) 15 (6.3%) 106 (11.4%) 8 (11.3%) 114 (11.4%) 120 (14.1%) 24 (22.0%) 144 (15.0%)
06 37 (19.8%) 12 (24%) 49 (20.7%) 184 (19.8%) 11 (15.5%) 195 (19.5%) 232 (27.2%) 23 (21.1%) 255 (26.5%)
07 20 (10.7%) 8 (16%) 28 (11.8%) 95 (10.2%) 11 (15.5%) 106 (10.6%) 167 (19.6%) 19 (17.4%) 186 (19.3%)
08 9 (4.8%) 2 (4%) 11 (4.6%) 79 (8.5%) 5 (7.0%) 84 (8.4%) 57 (6.7%) 6 (5.5%) 63 (6.5%)
09 4 (2.1%) 1 (2%) 5 (2.1%) 7 (0.8%) 0 (0%) 7 (0.7%) 24 (2.8%) 3 (2.8%) 27 (2.8%)
10 4 (2.1%) 0 (0%) 4 (1.7%) 11 (1.2%) 0 (0%) 11 (1.1%) 12 (1.4%) 3 (2.8%) 15 (1.6%)
Pooled data from two previous studies that have tested well defined PP-MS patients5 21 are compared with data from the current study.
MS, multiple sclerosis; PP, primary progressive; RR, relapsing-remitting; SP, secondary progressive.
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14 of these 19 genotypes contained an allele encoding HLA-
DR molecules using a glutamic acid at b171 or b174. In
contrast, of 15 genotypes occurring in patients with RR/SP-
MS, but not in patients with PP-MS, only four contained an
allele encoding HLA-DR molecules with a glutamic acid at
b171 or b174.
The percentages of DRB1*1501 positive or negative
individuals whose genotypes contained an allele encoding a
HLA-DRB1 molecule with a glutamic acid residue at b171 or
b174 are shown in table 3. The percentages of PP-MS patients
carrying such alleles were significantly increased compared
with the corresponding percentages of RR/SP-MS patients in
both the DRB1*1501 positive and DRB1*1501 negative
groups. In the DRB1*1501 positive group, this difference
was almost entirely caused by DR6 alleles, which made up
78% of alleles encoding HLA-DR molecules with a glutamic
acid residue at b171 or b174; however, in the DRB1*1501
negative group, both DR4 and DR6 alleles contributed
equally. None of the MS patients had genotypes encoding
two HLA-DR molecules that both had glutamic acid residues
at b171 or b174, but 5% of controls carried such genotypes.
HLA-DQA1 and HLA-DQB1 allele genotype
frequencies in PP-MS and RR/SP-MS
In insulin dependent diabetes mellitus, susceptibility to
disease has been linked to carriage of particular HLA-DQ
alleles35 rather than to the HLA-DR alleles with which they
are in linkage disequilibrium. In MS, it has been suggested
that HLA-DQ is more closely associated with disease in Afro-
Brazilian patients than is HLA-DR36; however, in white MS
patients, HLA-DR linkages appear to be the strongest. We
investigated whether there were differences between PP-MS
and RR/SP-MS in carriage of HLA-DQ alleles. The frequencies
of individuals carrying different HLA-DQA1 and HLA-DQB1
alleles are shown in table 4. As expected, DQA1*0102 and
DQ6 (which includes the allele DQB1*0602)—which are in
strong linkage disequilibrium with DRB1*1501—were found
significantly more often in PP-MS (pc,0.03) and RR/SP-MS
(pc,5.6610
24) than in controls (p values corrected for 40
comparisons). There were no significant differences between
PP-MS and RR/SP-MS when results were corrected for
multiple comparisons. To test further for associations
between MS and alleles other than those carried in the
HLA-DRB1*1501–DQA1*0102–DQB1*0602 haplotype, allelic
frequencies were compared in patients and controls after
removal of the DQA1*0102 and DQB1*0602 alleles occurring
as part of this haplotype. In the absence of these alleles there
were no significant differences in frequency between MS
patients and controls or between PP-MS patients and RR/SP-
MS patients for any HLA-DQ alleles (data not shown).
DISCUSSION
The question of whether or not the HLA molecules carried by
a patient with MS can influence the clinical course of disease
Table 2 Phenotype frequencies of alleles encoding HLA-DR molecules containing a
glutamic acid residue at b171 or b174
Serological group* DRB1 allele
PP-MS
(n = 50)
RR/SP-MS
(n = 71)
Controls
(n = 109)
DR1 0103 2 (4%) 2 (2.8%) 4 (3.7%)
DR4 0402 2 (4%) 1 (1.4%) 0 (0%)
0403 0 (0%) 0 (0%) 7 (6.4%)
0406 0 (0%) 0 (0%) 1 (0.9%)
0407 4 (8%) 0 (0%) 6 (5.5%)
DR5 1103 0 (0%) 0 (0%) 1 (0.9%)
DR6 1301 2 (4%) 3 (4.2%) 3 (2.8%)
1302 5 (10%) 2 (2.8%) 8 (7.3%)
1401 4 (8%) 1 (1.4%) 7 (6.4%)
1404 0 (0%) 0 (0%) 1 (0.9%)
1405 0 (0%) 0 (0%) 1 (0.9%)
1407 0 (0%) 0 (0%) 1 (0.9%)
DR9 0901 1 (2%) 0 (0%) 3 (2.8%)
Glutamic acid at b71 or b74 of DRB1 20 (40%) 9 (12.7%)` 38 (34.9%)
DR53 DRB4 (all alleles) 22 (44%) 26 (36.6%) 59 (54.1%)
*DR2, DR3, DR7, DR8, and DR10 alleles do not encode HLA-DR molecules containing a glutamic acid residue at
b171 or b174 and are therefore not included in the table.
Only alleles carried by patients and/or controls are shown.
`Significantly decreased in RR/SP-MS compared with PP-MS (odds ratio = 0.22 (0.09 to 0.54); pc = 0.02) and
compared with controls (0.27 (0.12 to 0.61); pc = 0.038); p values are corrected for 42 comparisons.
MS, multiple sclerosis; PP, primary progressive; RR, relapsing-remitting; SP, secondary progressive.
Table 3 Percentages of genotypes that contain alleles encoding HLA-DRB1 molecules
having a glutamic acid residue at position 71 or 74 of the b chain
Genotype Group Number
Number encoding
Glu71/74 (%) OR (PP-MS v RR/SP-MS)
All PP-MS 50 20 (40%) OR=4.6 (1.9 to 11.3)
RR/SP-MS 71 9 (12.7%)
Controls 109 43 (39.4%)
DRB1*1501
positive
PP-MS 31 8 (25.8%) OR=3.7 (1.0 to 13.7)
RR/SP-MS 47 4 (8.5%)
Controls 26 6 (23.1%)
DRB1*1501
negative
PP-MS 19 12 (63.2%) OR=6.5 (1.7 to 25.3)
RR/SP-MS 24 5 (20.8%)
Controls 83 32 (32%)
MS, multiple sclerosis; OR, odds ratio; PP, primary progressive; RR, relapsing-remitting; SP, secondary
progressive.
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has been debated now for almost 20 years. Several factors
have made it difficult to draw firm conclusions. These have
included unclear definition of patient subgroups (such as the
grouping of SP-MS and PP-MS), small PP-MS patient
numbers, and the analysis of HLA only at the level of
serologically defined groups. Most attention has focused on
HLA-DRB1*1501, as this allele correlates with susceptibility
to disease in numerous studies.11–13 16 20 21 37–39 However, in
HLA heterozygous individuals, who make up the majority of
people with MS, the immune system recognises antigen
presented not only by DRB1*1501 but also by the HLA
molecules encoded by the other alleles in the genotype. In
several other autoimmune diseases—including insulin
dependent diabetes mellitus, rheumatoid arthritis, and
Addison’s disease—it has been shown that combinations of
certain alleles in the genotype can affect the development of
disease35 40 or the disease course.41 42
Our results suggest that the presence of alleles encoding
HLA-DR molecules containing a negatively charged glutamic
acid residue at b171 or b174 protects against the development
of a relapsing–remitting course or increases the susceptibility
to a primary progressive course of disease, or both. HLA-DR
genotypes consisting of one of these alleles, with or without
DRB1*1501, are significantly decreased in patients with RR/
SP-MS in comparison with those with PP-MS. As the
antigens involved in the development of the different clinical
forms of MS have not been defined, it is difficult to determine
whether these alleles actively participate in the development
of a primary progressive course. If, as has been suggested,6
PP-MS differs from RR/SP-MS only in that the relapsing–
remitting phase is subclinical, then another possible inter-
pretation of the data in the current study is that carriage of
alleles encoding HLA-DR molecules containing a negatively
charged glutamic acid residue at b171 or b174 prevents the
initial relapsing–remitting phase of disease.
This correlation between the clinical course of MS and the
occurrence of alleles encoding HLA-DR molecules containing
a negatively charged glutamic acid residue in pocket 4 of the
antigen binding groove has not been noted previously
because only two studies have been published using a group
of more than 20 PP-MS patients,5 21 and for both of these HLA
typing was presented only in terms of the serological groups.
Thus it is not possible to estimate from those studies the
percentage of PP-MS patients carrying alleles containing a
negatively charged glutamic acid residue in pocket 4. There
are no other published molecular typing studies using well
defined PP-MS patients.
The amino acids found at b171 or b174 of the HLA molecule,
together with those at positions 13, 70, and 78 of the b1
chain, and at positions 9 and 62 of the a chain, influence the
shape and charge of pocket 4 of the particular HLA-DR
molecule.26 27 This is illustrated in fig 1 for DRB1*0404 and
DRB1*0407, which differ in pocket 4 only at b171; this residue
is an alanine (non-charged, hydrophobic) in DRB1*0404 and
a glutamic acid (acidic side chain) in DRB1*0407.
Pocket 4 has been shown to be critically important in the
binding of the immunodominant peptide (residues 84–102)
of myelin basic protein, a putative autoantigen in MS,43 to
DRB1*1501 in patients with RR-MS.44 For that particular
peptide/HLA combination, a large, predominantly hydropho-
bic uncharged pocket 4 is required to accommodate the large
aromatic side chain of a phenylalanine residue. Studies in
other MHC class II restricted autoimmune diseases such as
rheumatoid arthritis, pemphigus vulgaris, systemic lupus
erythematosus, and Hashimoto’s thyroiditis have also shown
that b171 and/or b174 play a critical role in the recognition of
the HLA-DR/peptide complex by CD4+ helper T cells.45–49 In
rheumatoid arthritis, for example, the peptides that bind to
proteins encoded by DRB1*04 alleles that are positively
(DRB1*0404) or negatively (DRB1*0402) associated with
disease have been characterised.49 These peptides all have
identical requirements at the anchor residues at peptide
positions p1 and p6, but substantially different requirements
at position p4 (the residue that binds in pocket 4 of the HLA
molecule). DRB1*0402, which has a negatively charged
glutamic acid at b171, binds peptides with a positive charge
at p4, whereas the presence of the positively charged arginine
residue at b171 in DRB1*0404 correlates with binding of
peptides with a negative charge at p4.
The pocket 4 region of HLA-DR molecules is also important
in non-autoimmune inflammatory diseases mediated by
CD4+ helper T cells. For example, the presence of a positively
charged arginine at positions b170 or b171 is associated
with susceptibility to tuberculoid leprosy.50 In contrast,
chronic beryllium disease—a lung disease caused by the
accumulation in the lung of beryllium specific CD4+ MHC
class II restricted T cells—is associated with the presence
of a glutamic acid at residue 69 of the DPB1 molecule.51
Residue 69 of the DP b chain corresponds to b171 of the DR
chain.
Some studies have suggested a trend towards increased
carriage of DR4 in patients with PP-MS compared with those
with RR/SP-MS,16 21 38 although this difference has not
reached statistical significance in any study. In the current
study, there were no differences in the overall frequency of
DR4 alleles in PP-MS compared with RR/SP-MS, although
more PP-MS patients carried DRB1*0402 or *0407—which
encode HLA-DR molecules containing a glutamic acid residue
at b171 or b174—than did RR/SP-MS patients (12.0% v 1.4%,
respectively). In particular, DRB1*1501 negative PP-MS
patients showed an increased frequency of these alleles in
the genotype compared with DRB1*1501 negative RR/SP-MS
patients (p=0.036 by Fisher’s exact test). It is therefore
possible that the previously reported DR4 association with
PP-MS16 21 38 may have reflected the presence of alleles
encoding HLA-DR molecules containing glutamic acid at
b171 or b174.
The most obvious effect of the change in shape, size, or
charge of pocket 4 would be on the ability of the particular
HLA molecule to bind a disease relevant peptide; however, it
Table 4 Phenotype frequencies for HLA-DQA1 and
DQB1 alleles
DQA1
allele
PP-MS
(n = 50)
RR/SP-MS
(n = 71)
Controls
(n = 109)
0101 12 (24%) 9 (12.7%) 29 (26.6%)
0102 33 (66%)* 49 (69.0%)** 42 (38.5%)
0103 3 (6%) 5 (7.0%) 5 (4.6%)
0104 2 (4%) 0 (0%) 0 (0%)
0105 0 (0%) 1 (1.4%) 0 (0%)
0201 7 (14%) 11 (15.5%) 23 (21.1%)
0301 10 (20%) 17 (23.9%) 35 (32.1%)
0302 1 (2%) 1 (1.4%) 1 (0.9%)
0303 4 (8%) 0 (0%) 0 (0%)
0401 1 (2%) 3 (4.2%) 5 (4.6%)
0501 19 (38%) 29 (40.8%) 51 (46.8%)
0503 1 (2%) 0 (0%) 0 (0%)
0601 0% 1 (1.4%) 0 (0%)
DQB serological group
DQ5(1) 16 (32%) 13 (18.3%) 37 (33.9%)
DQ6(1) 38 (76%)** 52 (73.2%)** 43 (39.4%)
DQ2 17 (34%) 28 (39.4%) 44 (40.4%)
DQ7(3) 12 (24%) 17 (23.9%) 37 (33.9%)
DQ8(3) 7 (14%) 6 (8.5%) 6 (5.5%)
DQ9(3) 5 (10%) 7 (9.9%) 20 (18.3%)
DQ4 1 (2%) 4 (5.6%) 8 (7.3%)
*pc,0.03 v controls; **pc,0.002 v controls.
MS, multiple sclerosis; PP, primary progressive; RR, relapsing-remitting;
SP, secondary progressive.
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is also possible that the DR4, DR6, and other HLA molecules
that contain a glutamic acid at b171 or b174 are encoded by
alleles that are in linkage disequilibrium with some other site
within the MHC region which could affect the disease course.
We did not find any evidence to suggest that HLA-DQ alleles
account for the differences seen between PP-MS and RR/SP-
MS (table 4); however, the HLA region is also in strong
linkage disequilibrium with genes encoding, for example, the
cytokine tumour necrosis factor (TNF) and the molecule
IkBL, a member of the IkB family of inhibitory factors that
are involved in control of the pro-inflammatory transcription
factor, NF-kB. Several polymorphisms are known to occur in
TNF and IKBL genes.52 Patients carrying HLA alleles in
linkage disequilibrium with such polymorphisms could have
altered inflammatory immune responses, thus leading to a
different clinical course of disease.
Not all PP-MS patients carried alleles encoding HLA-DR
molecules containing a glutamic acid residue at b171 or b174,
and some RR/SP patients did carry such alleles. This probably
reflects the heterogeneity in disease pathogenesis. Overall,
however, there was a clear cut difference between the two
groups of MS patients, which suggests that—in some cases at
least—the HLA genotype can exert an influence on the
clinical course of MS. The results from the study of Zipp
et al34 and from the large serotyping studies from Sweden5
and Northern Ireland21 provide indirect support for this
hypothesis.
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Robert Ba´ra´ny 1876–1936
R
obert Ba´ra´ny was educated at the University of Vienna,
graduating in medicine in 1900. In 1903, he accepted an
appointment at the University of Vienna otology clinic
working in the department of Adam Politzer, who had
established the speciality in Austria. Here he began his
studies exploring the equilibrium system of the ear and the
brain. Among his contributions was a test, now called the
Ba´ra´ny test, for diagnosing diseases of the semicircular canals
of the inner ear by syringing the ear with either hot or cold
water. He noted nystagmus when the water was above or
below, but not at body temperature. He concluded that with
caloric nystagmus, the endolymph, normally at body tem-
perature, displaced itself when it came into contact with
water at other temperatures, and that the vestibular nerve
transmitted the thermal disturbance within the endolymph
to the brain. His work led to the development of the Ba´ra´ny
rotating chair, which demonstrated the relationship between
the vestibular system, the nervous system, and centres within
the cerebellum. In 1913, he investigated the somatopic
localisation in the cerebellum and postulated that the vermis
was concerned with coordinated movements of the trunk, the
hemisphere with the extremities, and the flocculus with
movements of the eyes.
Ba´ra´ny received the Nobel Prize in 1914 for his develop-
ment of clinical investigation of the human equilibrium
system. He essentially founded a new area of medical science
and practice. At the time of this award, which was delayed
until 1915 by the outbreak of World War I, he was a prisoner
of war in Siberia. When Austria entered the war, Ba´ra´ny saw
an opportunity to investigate his ideas with brain injured
soldiers. He volunteered for medical service and was assigned
to the fortress of Przemysl in Galicia (now Poland) to provide
care for 123 000 men. There he built an otolaryngology unit,
and developed a very successful primary suture technique for
the suture of head wounds. He was captured there by
advancing Russian troops in April 1915 and taken prisoner.
After Prince Carl of Sweden persuaded Czar Nicholas 1 to
release Ba´ra´ny, the Swedish Red Cross negotiated his release
and emigration to Sweden. He became director of the
otorhinolaryngology clinic at the University of Uppsala,
Sweden in 1917, and in 1926 became a full professor there.
In 1921 he became the first to describe positional vertigo.
Upon his death, the University of Uppsala established the
Ba´ra´ny medal, to be awarded at 5 year intervals to the most
outstanding scientist in the field of the vestibular research.
The Ba´ra´ny society was founded in his honour by C S
Hallpike and C O Nylen in 1960.
Ba´ra´ny is portrayed here on a stamp issued by Austria in
1976, the centenary of his birth (Stanley Gibbons no. 1756,
Scott no. 1031).
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